William Blair analyst Sami Corwin has maintained their neutral stance on SRPT stock, giving a Hold rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sami Corwin has given his Hold rating due to a combination of factors impacting Sarepta Therapeutics. The FDA’s approval to start ENDEAVOR Cohort 8 is seen as a positive development, potentially addressing safety concerns for nonambulatory patients. The inclusion of sirolimus in the treatment regimen aligns with expert recommendations and could help restore the expanded label if successful, with potential label reinstatement by 2027.
However, the stock’s short-term growth prospects appear limited. The recent failure of the ESSENCE trial poses a risk to the marketing authorization of Vyondys 53 and Amondys 45. Additionally, there is uncertainty surrounding Elevidys’ revenue guidance for upcoming quarters. Furthermore, Sarepta’s financials are impacted by a $200 million milestone payment to Arrowhead, contributing to a projected net loss of $760 million.
Corwin covers the Healthcare sector, focusing on stocks such as Neurogene, uniQure, and Kyverna Therapeutics, Inc.. According to TipRanks, Corwin has an average return of 11.5% and a 49.59% success rate on recommended stocks.
In another report released today, Bernstein also maintained a Hold rating on the stock with a $20.00 price target.